Vitamin K2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites
Background There is insufficient evidence for the ability of vitamin K2 to improve type 2 diabetes mellitus symptoms by regulating gut microbial composition. Herein, we aimed to demonstrate the key role of the gut microbiota in the improvement of impaired glycemic homeostasis and insulin sensitivity by vitamin K2 intervention. Methods We first performed a 6-month RCT on 60 T2DM participants with or without MK-7 (a natural form of vitamin K2) intervention. In addition, we conducted a transplantation of the MK-7-regulated microbiota in diet-induced obesity mice for 4 weeks. 16S rRNA sequencing, fecal metabolomics, and transcriptomics in both study phases were used to clarify the potential mechanism. Results After MK-7 intervention, we observed notable 13.4%, 28.3%, and 7.4% reductions in fasting serum glucose (P = 0.048), insulin (P = 0.005), and HbA1c levels (P = 0.019) in type 2 diabetes participants and significant glucose tolerance improvement in diet-induced obesity mice (P = 0.005). Moreover, increased concentrations of secondary bile acids (lithocholic and taurodeoxycholic acid) and short-chain fatty acids (acetic acid, butyric acid, and valeric acid) were found in human and mouse feces accompanied by an increased abundance of the genera that are responsible for the biosynthesis of these metabolites. Finally, we found that 4 weeks of fecal microbiota transplantation significantly improved glucose tolerance in diet-induced obesity mice by activating colon bile acid receptors, improving host immune-inflammatory responses, and increasing circulating GLP-1 concentrations. Conclusions Our gut-derived findings provide evidence for a regulatory role of vitamin K2 on glycemic homeostasis, which may further facilitate the clinical implementation of vitamin K2 intervention for diabetes management. Trial registration The study was registered at https://www.chictr.org.cn (ChiCTR1800019663)..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
BMC medicine - 21(2023), 1 vom: 05. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yuntao [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Fecal metabolites |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s12916-023-02880-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05031534X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05031534X | ||
| 003 | DE-627 | ||
| 005 | 20230506064758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230506s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12916-023-02880-0 |2 doi | |
| 035 | |a (DE-627)SPR05031534X | ||
| 035 | |a (SPR)s12916-023-02880-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yuntao |e verfasserin |0 (orcid)0000-0003-1229-1450 |4 aut | |
| 245 | 1 | 0 | |a Vitamin K2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background There is insufficient evidence for the ability of vitamin K2 to improve type 2 diabetes mellitus symptoms by regulating gut microbial composition. Herein, we aimed to demonstrate the key role of the gut microbiota in the improvement of impaired glycemic homeostasis and insulin sensitivity by vitamin K2 intervention. Methods We first performed a 6-month RCT on 60 T2DM participants with or without MK-7 (a natural form of vitamin K2) intervention. In addition, we conducted a transplantation of the MK-7-regulated microbiota in diet-induced obesity mice for 4 weeks. 16S rRNA sequencing, fecal metabolomics, and transcriptomics in both study phases were used to clarify the potential mechanism. Results After MK-7 intervention, we observed notable 13.4%, 28.3%, and 7.4% reductions in fasting serum glucose (P = 0.048), insulin (P = 0.005), and HbA1c levels (P = 0.019) in type 2 diabetes participants and significant glucose tolerance improvement in diet-induced obesity mice (P = 0.005). Moreover, increased concentrations of secondary bile acids (lithocholic and taurodeoxycholic acid) and short-chain fatty acids (acetic acid, butyric acid, and valeric acid) were found in human and mouse feces accompanied by an increased abundance of the genera that are responsible for the biosynthesis of these metabolites. Finally, we found that 4 weeks of fecal microbiota transplantation significantly improved glucose tolerance in diet-induced obesity mice by activating colon bile acid receptors, improving host immune-inflammatory responses, and increasing circulating GLP-1 concentrations. Conclusions Our gut-derived findings provide evidence for a regulatory role of vitamin K2 on glycemic homeostasis, which may further facilitate the clinical implementation of vitamin K2 intervention for diabetes management. Trial registration The study was registered at https://www.chictr.org.cn (ChiCTR1800019663). | ||
| 650 | 4 | |a Vitamin K2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Type 2 diabetes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Gut microbiota |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fecal metabolites |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Glycemic homeostasis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Liu, Lin |4 aut | |
| 700 | 1 | |a Wei, Chunbo |4 aut | |
| 700 | 1 | |a Wang, Xuanyang |4 aut | |
| 700 | 1 | |a Li, Ran |4 aut | |
| 700 | 1 | |a Xu, Xiaoqing |4 aut | |
| 700 | 1 | |a Zhang, Yingfeng |4 aut | |
| 700 | 1 | |a Geng, Guannan |4 aut | |
| 700 | 1 | |a Dang, Keke |4 aut | |
| 700 | 1 | |a Ming, Zhu |4 aut | |
| 700 | 1 | |a Tao, Xinmiao |4 aut | |
| 700 | 1 | |a Xu, Huan |4 aut | |
| 700 | 1 | |a Yan, Xuemin |4 aut | |
| 700 | 1 | |a Zhang, Jia |4 aut | |
| 700 | 1 | |a Hu, Jinxia |4 aut | |
| 700 | 1 | |a Li, Ying |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC medicine |d London : BioMed Central, 2003 |g 21(2023), 1 vom: 05. Mai |w (DE-627)SPR02834149X |w (DE-600)2131669-7 |x 1741-7015 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:1 |g day:05 |g month:05 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12916-023-02880-0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 1 |b 05 |c 05 | ||